Readystate Asset Management LP Acquires Shares of 20,933 CRISPR Therapeutics AG $CRSP

Readystate Asset Management LP bought a new position in CRISPR Therapeutics AG (NASDAQ:CRSP) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 20,933 shares of the company’s stock, valued at approximately $996,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of CRSP. Mcguire Capital Advisors Inc. bought a new stake in CRISPR Therapeutics in the 4th quarter worth approximately $25,000. Ramirez Asset Management Inc. purchased a new stake in shares of CRISPR Therapeutics during the 4th quarter worth approximately $26,000. Rothschild Investment LLC boosted its position in shares of CRISPR Therapeutics by 836.7% during the 4th quarter. Rothschild Investment LLC now owns 562 shares of the company’s stock valued at $29,000 after acquiring an additional 502 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. boosted its position in shares of CRISPR Therapeutics by 196.9% during the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 576 shares of the company’s stock valued at $30,000 after acquiring an additional 382 shares during the last quarter. Finally, Oakworth Capital Inc. purchased a new position in shares of CRISPR Therapeutics in the fourth quarter valued at $34,000. Institutional investors own 69.20% of the company’s stock.

Insider Buying and Selling at CRISPR Therapeutics

In other news, insider Naimish Patel sold 3,786 shares of the firm’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $55.62, for a total value of $210,577.32. Following the completion of the transaction, the insider directly owned 19,357 shares in the company, valued at $1,076,636.34. This trade represents a 16.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 5.20% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Evercore restated an “outperform” rating and issued a $76.00 price target on shares of CRISPR Therapeutics in a research report on Monday, May 11th. Citizens Jmp reiterated a “market outperform” rating and set a $80.00 price objective on shares of CRISPR Therapeutics in a research report on Monday, July 6th. UBS Group set a $80.00 price objective on shares of CRISPR Therapeutics in a research note on Friday, June 12th. Morgan Stanley set a $60.00 target price on shares of CRISPR Therapeutics and gave the stock an “equal weight” rating in a report on Thursday, June 11th. Finally, Sanford C. Bernstein increased their price target on shares of CRISPR Therapeutics from $50.00 to $56.00 and gave the company a “market perform” rating in a report on Wednesday, May 13th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $67.78.

CRISPR Therapeutics Stock Performance

Shares of CRISPR Therapeutics stock opened at $47.64 on Thursday. The company has a current ratio of 17.97, a quick ratio of 17.96 and a debt-to-equity ratio of 0.32. The stock’s fifty day moving average price is $52.60 and its 200-day moving average price is $52.49. The firm has a market cap of $4.59 billion, a P/E ratio of -7.66 and a beta of 1.71. CRISPR Therapeutics AG has a 12 month low of $44.12 and a 12 month high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Tuesday, March 31st. The company reported ($1.28) EPS for the quarter. CRISPR Therapeutics had a negative return on equity of 25.66% and a negative net margin of 13,856.54%.The company had revenue of $1.46 million during the quarter. On average, equities research analysts expect that CRISPR Therapeutics AG will post -4.9 earnings per share for the current fiscal year.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent ?-thalassemia in collaboration with Vertex Pharmaceuticals.